Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alma Osmanovic

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Neurology|September 26, 2019
Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersenClaudia D Wurster, Petra Steinacker, René Günther, et al.
Brain Sciences|March 3, 2021
Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy PatientsLars Hendrik Müschen, Alma Osmanovic, Camilla Binz, et al.
Brain Sciences|January 21, 2023
Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers-A Prospective, Cross-Sectional, Multi-Center AnalysisCamilla Wohnrade, Ann-Kathrin Velling, Lucas Mix, et al.
Therapeutic Advances in Neurological Disorders|March 22, 2021
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapyAlma Osmanovic, Gresa Ranxha, Mareike Kumpe, et al.
European Journal of Neurology|November 1, 2025
Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q-Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational StudyBogdan Bjelica, Camilla Wohnrade, Alma Osmanovic, et al.
Annals of Clinical and Translational Neurology|February 22, 2022
Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophyCamilla Binz, Alma Osmanovic, Nele H Thomas, et al.
Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.
European Journal of Human Genetics : EJHG|August 18, 2011
Identification and functional analysis of novel THAP1 mutationsKatja Lohmann, Nils Uflacker, Alev Erogullari, et al.
European Journal of Neurology|May 7, 2021
Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersenThomas Meyer, André Maier, Zeljko Uzelac, et al.
Brain Sciences|July 2, 2021
Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers' LivesPavel Schischlevskij, Isabell Cordts, René Günther, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Neurology|September 26, 2019
Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersenClaudia D Wurster, Petra Steinacker, René Günther, et al.
Brain Sciences|March 3, 2021
Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy PatientsLars Hendrik Müschen, Alma Osmanovic, Camilla Binz, et al.
Brain Sciences|January 21, 2023
Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers-A Prospective, Cross-Sectional, Multi-Center AnalysisCamilla Wohnrade, Ann-Kathrin Velling, Lucas Mix, et al.
Therapeutic Advances in Neurological Disorders|March 22, 2021
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapyAlma Osmanovic, Gresa Ranxha, Mareike Kumpe, et al.
European Journal of Neurology|November 1, 2025
Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q-Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational StudyBogdan Bjelica, Camilla Wohnrade, Alma Osmanovic, et al.
Annals of Clinical and Translational Neurology|February 22, 2022
Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophyCamilla Binz, Alma Osmanovic, Nele H Thomas, et al.
Annals of Clinical and Translational Neurology|April 1, 2021
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatmentMaren Freigang, Claudia D Wurster, Tim Hagenacker, et al.
European Journal of Human Genetics : EJHG|August 18, 2011
Identification and functional analysis of novel THAP1 mutationsKatja Lohmann, Nils Uflacker, Alev Erogullari, et al.
European Journal of Neurology|May 7, 2021
Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersenThomas Meyer, André Maier, Zeljko Uzelac, et al.
Brain Sciences|July 2, 2021
Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers' LivesPavel Schischlevskij, Isabell Cordts, René Günther, et al.
Pageof 5